Morphological changes of intestinal mucosa in patients with different clinical variants of irritable bowel syndrome using tetracyclic antidepressants and selective serotonin reuptake inhibitor.

Authors

  • S. Nagieva Національний медичний університет імені О.О. Богомольця, Ukraine
  • A. Svintsitskyy Національний медичний університет імені О.О. Богомольця, Ukraine
  • O. Kuryk МЦ «Універсальна клініка « Оберіг»» ТОВ «Капитал» Державна наукова установа «Науково-практичний центр профілактичної та клінічної медицини» Державного управління справами, Київ, Ukraine
  • I. Korendovych Національний медичний університет імені О.О. Богомольця, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2015.4.49-56

Keywords:

irritable bowel syndrome, biopsy, colonic mucosa, infiltration, inflammation

Abstract

Objective. To assess histological changes of colonic mucosa in patients with clinically different types of irritable bowel syndrome (IBS) before and after the treatment with tetracyclic antidepressant and selective serotonin reuptake inhibitor. Methods. Adult patients (over 18 years) with confirmed diagnosis of IBS were examined. Biopsy specimens were taken from colon during colonoscopy for the next histological examination. One expert gastrointestinal pathologist assessed all tissue samples. We patent semi quantitative assessment of the severity of cell infiltration of colonic mucosa, which could be assessed as inflammatory (neutrophils), immune (lymphocytes, plasma cells, macrophages), or allergic (eosinophils) response (0 to 3 degrees). All patients received treatment due to the clinical variant of IBS: 1) IBS-constipation – mirtazapinum 15 mg/night+lactulose 30ml/morning (+30ml/night if needed); 2) IBS-diarrhea – escitalopram 5mg/night+rifaximine 600mg/twice a day; 3) IBS-unspecified – mirtazapinum 15 mg/escitalopram 5mg/ night; 4) IBS-mixed – mirtazapinum 15 mg, lactulose 30ml/morning (+30ml/night if needed) / escitalopram 5mg/night+rifaximine 600mg/twice a day. Results. 107 patients were examined, 36 of them had constipation (I group), 35 – diarrhea (II group), 22- unspecified variant (III group) and 12 patients had mixed variant of IBS (IV group) due to Rome III criteria (2006). 1st degree of lymphocyte infiltration was detected in 100% IBS-constipation patients and in 58,3% IBS-mixed variant (p<0.01). 1st degree of macrophage infiltration was seen in all patients except IBS-diarrhea (p<0.05). 2nd degree of lymphocyte infiltration was detected in 82,1% IBS-diarrhea patients and in 66,7% IBS-unspecified variant (p<0.01). 2nd degree of macrophage infiltration was seen in all patients except IBS-constipation, but more often in IBS-diarrhea (p<0.001). After the treatment we revealed the reduction of the degree of inflammation in all four groups of patients (zero and 1st degree, p>0.05). No cases of 2nd or 3rd degree of colonic mucosa infiltration were found. Conclusion. After the treatment with tetracyclic antidepressant and selective serotonin reuptake inhibitor we found that the degree of inflammation of colonic mucosa was reduced or disappeared, due to the zero degree of infiltration according to our patented classification.

References

  1. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009 Jan;104 Suppl 1:S1-35. doi: 10.1038/ajg.2008.122.
  2. Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut. 2008 Jun;57(6):756-63. doi: 10.1136/gut.2007.142810..
  3. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D, Baxter K, Ryks M, Zinsmeister AR. Prospective study of motor, senso-ry, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008 Jul;6(7):772-81. doi: 10.1016/j.cgh.2008.02.060.
  4. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology. 2006 Apr;130(5):1377-90.
  5. Talley NJ. Functional gastrointestinal dis-orders as a public health problem. Neurogastroenterol Motil. 2008 May;20 Suppl 1:121-9. doi: 10.1111/j.1365-2982.2008.01097.x.
  6. Saito YA, Talley NJ. Genetics of irritable bowel syndrome. Am J Gastroenterol. 2008 Aug;103(8):2100-4; quiz 2105. doi: 10.1111/j.1572-0241.2008.02048.x.
  7. Saito YA, Strege PR, Tester DJ, Locke GR 3rd, Talley NJ, Bernard CE, Rae JL, Makielski JC, Ackerman MJ, Farrugia G. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G211-8. doi: 10.1152/ajpgi.90571.2008.
  8. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57.
  9. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73. doi: 10.1038/nrgastro.2010.4.
  10. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2008 Aug 15;28(4):385-96. doi: 10.1111/j.1365-2036.2008.03750.x.

Downloads

How to Cite

Nagieva, S., Svintsitskyy, A., Kuryk, O., & Korendovych, I. (2015). Morphological changes of intestinal mucosa in patients with different clinical variants of irritable bowel syndrome using tetracyclic antidepressants and selective serotonin reuptake inhibitor. Морфологія / Morphologia / Morfologìâ, 9(4), 49–56. https://doi.org/10.26641/1997-9665.2015.4.49-56

Issue

Vol. 9 No. 4 (2015)

Section

Статті

License

Copyright (c) 2018 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.